A Dark Vector Cognition product

Item 6. Exhibits

4K characters. Original on sec.gov · Markdown

Item 6. Exhibits

Exhibit NumberExhibit Description
2.1^Agreement and Plan of Merger by and among Crinetics Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, and Clark Merger Sub, Inc. dated July 6, 2026 (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission by Crinetics Pharmaceuticals, Inc. on July 6, 2026).
10.1Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan dated (incorporated by reference to Exhibit 99.1 to the Registration Statement on Form S-8 filed with the Securities and Exchange Commission by Vertex Pharmaceuticals Incorporated on May 13, 2026).*
10.2Form of Restricted Stock Unit Agreement under the 2026 Stock and Option Plan.*
10.3Form of Restricted Stock Unit Agreement (with Performance Conditions) under the 2026 Stock and Option Plan.*
10.4Form of Restricted Stock Unit Agreement (for Non-Employee Directors) under the 2026 Stock and Option Plan.*
10.5Form of Option Agreement (for Non-Employee Directors) under the 2026 Stock and Option Plan.*
10.6Non-Employee Director Deferred Compensation Plan.*
31.1Certification of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
31.2Certification of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
32.1Certification of the Chief Executive Officer and the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.
101.INSXBRL Instance - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHXBRL Taxonomy Extension Schema
101.CALXBRL Taxonomy Extension Calculation
101.LABXBRL Taxonomy Extension Labels
101.PREXBRL Taxonomy Extension Presentation
101.DEFXBRL Taxonomy Extension Definition
104Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
^Schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule will be furnished supplementally to the SEC upon request.
*Management contract, compensatory plan or agreement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be

signed on its behalf by the undersigned thereunto duly authorized.

Vertex Pharmaceuticals Incorporated
August 4, 2026By:/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President, Chief Operating & Financial Officer (principal financial officer and duly authorized officer)

Previous: Item 5. Other Information